medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2017, Number 3

<< Back Next >>

Rev Mex Urol 2017; 77 (3)

Circulating miRNA expression as a clinical option for the detection of prostate cancer

Rodríguez-Báez Á, Comoto-Santacruz DA, Huerta-Núñez LFE, Campos-Saucedo JG, Estrada-Carrasco CE

Language: Spanish
References: 37
Page: 199-206
PDF size: 206.82 Kb.


ABSTRACT

Background: MicroRNA molecules are altered in cancerous prostate tissue. This is also true in the drug-resistant cases. MicroRNAs are important regulators of gene expression and they are involved in various pathologic processes. These molecules have been reported as diagnostic, prognostic, and treatment response biomarkers in prostate cancer.
Objective: To determine the microRNA expression profile through molecular biology techniques in patients with prostate cancer. Materials and methods: A case-control study was conducted that analyzed blood samples from patients diagnosed with prostate cancer for serum total RNA extraction, cDNA synthesis, qRT-PCR, and microRNA expression analysis.
Results: Twenty blood samples were collected for molecular miRNA study. Sixty-two microRNAs were analyzed and 9 of them were revealed to have altered expression. Five of those 9 are reported in the international literature as castration-resistant prostate cancer markers.
Discussion and conclusions: There is clear evidence of the relation between miRNAs and their function in pathologic processes. For example, the miR-375 gene is related to proliferation and epithelial- mesenchymal transition; miR-143 is related to migration and invasion; and miR-31 is related to the androgen receptor. This could improve the biomarkers already established in prostate cancer. The identification of miRNAs through noninvasive methods is a useful tool for the detection and diagnosis of prostate cancer, as well as for the prognosis of patients at risk for developing drug resistance in relation to their treatment.


REFERENCES

  1. Jiménez-Ríos M, Solares-Sánchez M, Martínez-Cervera P, Aguilar-Ponce J, Martínez-Cedillo J, Hinojosa-Gómez J. Oncoguía: Cáncer de próstata. Cancerología 2011;6:13-18.

  2. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales, Cuernavaca, México: Instituto Nacional de Salud Pública 2012:1-196.

  3. Otero JR, Gómez BG, Juanatey FC, Touijer KA. Prostate cancer biomarkers: An update. Urologic oncology: Seminars and original investigations. Urol Oncol 2014:252-60.

  4. Lilja H. Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer. Clin Chem 2008; 54:1248-9.

  5. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nature Rev Cancer 2008;8:268-78.

  6. Cary KC, Cooperberg MR. Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol 2013;5:318-29.

  7. Saini S. PSA and beyond: alternative prostate cancer biomarkers. Cell Oncol 2016;39:97-106.

  8. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52.

  9. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Translat Med 2012;4:127rv3-rv3.

  10. Ilyin SE, Belkowski SM, Plata-Salamán CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotech 2004;22:411-6.

  11. Graves P, Zeng Y. Biogenesis of mammalian microRNAs: a global view. Genomics Proteomics Bioinformatics 2012;10:239-45.

  12. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.

  13. Jackson BL, Grabowska A, Ratan HL. MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers. BMC Cancer 2014;14:1.

  14. Li F, Mahato RI. MicroRNAs and drug resistance in prostate cancers. Mol Pharm 2014;11:2539-52.

  15. Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011;17:3876-83.

  16. Kim WT, Kim W-J. MicroRNAs in prostate cancer. Prostate international 2013;1:3-9.

  17. Ozen M, Creighton C, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008;27:1788-93.

  18. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-5.

  19. Gordanpour A, Nam R, Sugar L, Seth A. MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics. Prostate Cancer Prostatic Dis 2012;15:314-9.

  20. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res 2009;69:7495-8.

  21. Saini S, Majid S, Dahiya R. Diet, microRNAs and prostate cancer. Pharm Res 2010;27:1014-26.

  22. Szczyrba J, Löprich E, Wach S, et al. The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 2010;8:529-38.

  23. Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet 2014;21:36.

  24. Ambs S, Prueitt RL, Yi M, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-70.

  25. Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011;128:608-16.

  26. Selth LA, Townley S, Gillis JL, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 2012;131:652-61.

  27. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009;4:e6229.

  28. Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One 2013;8:e83991.

  29. Costa-Pinheiro P, Montezuma D, Henrique R, Jerónimo C. Diagnostic and prognostic epigenetic biomarkers in cancer. Epigenomics 2015;7:1003-15.

  30. Bertoli G, Cava C, Castiglioni I. MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer. Int J Mol Sci 2016;17:421.

  31. Jalava S, Urbanucci A, Latonen L, et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castrationresistant prostate cancer. Oncogene 2012;31:4460-71.

  32. Tian L, Fang YX, Xue JL, Chen JZ. Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PloS one 2013;8:e75885.

  33. Haldrup C, Kosaka N, Ochiya T, et al. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv Transl Res 2014;4:19-30.

  34. Lin P-C, Chiu Y-L, Banerjee S, et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013;73:1232-44.

  35. Peng X, Guo W, Liu T, et al. Identification of miRs-143 and- 145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PloS One 2011;6:e20341.

  36. He M, Liu Y, Deng X, et al. Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells. Prostate 2013;73:1048-56.

  37. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 2010;70:1501-12.




2020     |     www.medigraphic.com